Bemegride
Title: Bemegride
CAS Registry Number: 64-65-3
CAS Name: 4-Ethyl-4-methyl-2,6-piperidinedione
Additional Names: 3-ethyl-3-methylglutarimide; 4-ethyl-4-methyl-2,6-dioxopiperidine; 2,6-dioxo-4-methyl-4-ethylpiperidine; methetharimide; b,b-methylethylglutarimide
Manufacturers' Codes: NP-13
Trademarks: Eukraton (Nordmark); Megimide (Inibsa)
Molecular Formula: C8H13NO2
Molecular Weight: 155.19
Percent Composition: C 61.91%, H 8.44%, N 9.03%, O 20.62%
Literature References: Prepn: Thole, Thorpe, J. Chem. Soc. 99, 439 (1911); Sircar, ibid. 1937, 602, 604; Benica, Wilson, J. Am. Pharm. Assoc. Sci. Ed. 39, 451 (1950); Lukes, Ferles, Chem. Listy 49, 510 (1955), C.A. 49, 10290 (1955). Pharmacology: Delay et al., Presse Med. 64, 1525 (1956); Oberdorf, Meyer, Arch. Exp. Pathol. Pharmakol. 238, 128 (1960); Kretzschmar et al., Arch. Int. Pharmacodyn. Ther. 174, 318 (1968). Metabolism: Nicholls, Nature 185, 927 (1960). Toxicity study: F. Hahn, A. Oberdorf, Arch. Int. Pharmacodyn. Ther. 135, 9 (1962). Reduction of barbiturate anesthesia in mice: V. K. Patel et al., Psychopharmacology 71, 21 (1980). Postsynaptic effects: P. W. Gage, P. Sah, Br. J. Pharmacol. 75, 493 (1982).
Properties: Platelets from water or from acetone + ether, mp 127°. Sublimes at 100° and 2 mm press. Sol in water, acetone. LD50 in male mice (mg/kg): 20.1 ±1.41 i.v., 43.0 ±1.8 s.c.; LD50 in male rats (mg/kg): 16.3 ±1.24 i.v., 23.5 ±1.67 i.p (Hahn, Oberdorf).
Melting point: mp 127°
Toxicity data: LD50 in male mice (mg/kg): 20.1 ±1.41 i.v., 43.0 ±1.8 s.c.; LD50 in male rats (mg/kg): 16.3 ±1.24 i.v., 23.5 ±1.67 i.p (Hahn, Oberdorf)
Therap-Cat: CNS stimulant. Antidote (barbiturate poisoning).
Therap-Cat-Vet: CNS stimulant. Antidote (barbiturate poisoning).
Keywords: CNS Stimulant; Respiratory Stimulant.

Others monographs:
Bismuth GermanateFenofibrateArcitumomabSulfabenzamide
BAPTAHydroquinoneMevalonic AcidOxybutynin
StigmasterolChlorpropamideSelenium OxychlorideLevocabastine
TrimetozineSilver ChlorideCalcium 2-EthylbutanoateAllopregnane-3β,11β,21-triol-20-one
©2016 DrugLead US FDA&EMEA